Michael Healy-Rae
Ceist:411. Deputy Michael Healy-Rae asked the Minister for Health if he will include pain relief patches on the medical card (details supplied); and if he will make a statement on the matter. [5440/23]
Amharc ar fhreagraThursday, 2 February 2023
Ceisteanna (411)
Freagraí scríofa
The Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicinal products under the community drug schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013.
Reimbursement for medicines under the community drugs schemes is for licenced indications which have been granted market authorisation by the European Medicines Agency or the Health Products Regulatory Authority (HPRA).
The following pain relief patches are currently available on the Reimbursement list:
- Durogesic DTrans Transdermal patched
- Fental Matrix Transdermal patches
- Matrifen Transdermal patches
- Fentadur Transdermal patches
- Butrans Transdermal patches
- Versatis plasters (subject to a managed access system, indicated for post-herpetic neuralgia)
Patients prescribed Versatis plasters are reviewed by the Medicines Management Programme (MMP) for reimbursement approval, on foot of an application by the patient’s clinician, through the HSE online system.
In exceptional circumstances, Versatis plasters may be approved for supply for unlicensed uses. If an application is refused, the clinician may make an appeal to the MMP by email, making a clear clinical case for the patient.
This process ensures that post-shingles patients, and other patients as clinically appropriate, can continue to have this specific treatment.